Streetbeat News

Equity Actions

KDP

Keurig Dr Pepper (KDP) has announced that JAB, a long-term anchor shareholder, plans to sell up to 100 million shares of KDP's common stock. Concurrently, KDP will repurchase 35 million of these shares. Despite the sale, JAB intends to remain a long-term anchor shareholder in KDP.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:29 pm

HUMA

Humacyte shares are trading lower following the announcement of a proposed public offering of common stock. This move typically dilutes existing shareholders' equity, leading to a decrease in share price.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:26 pm

TSLX

Sixth Street Specialty Lending has announced a public offering of 4 million shares. This move is aimed at raising capital, potentially for further investments or operational purposes. The impact on the stock price and investor sentiment will depend on market perception of this expansion of capital.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:25 pm

COO

CooperCompanies has increased its FY24 total revenue forecast to $3.847B-$3.897B from the previous $3.809B-$3.877B, with an adjusted EPS forecast raised to $3.50-$3.58 from the prior $13.60-$14.00, reflecting adjustments from a four-for-one stock split effective February 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:22 pm

RILY

B. Riley Financial, Inc. is exploring strategic alternatives for its Appraisal and Retail, Wholesale & Industrial Solutions businesses. This review aims to enhance shareholder value and could include a range of options such as sales, partnerships, or other transactions.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:05 pm

HUMA

Humacyte, Inc. has announced a proposed public offering of its common stock. This move is aimed at raising capital, although the specific use of the proceeds was not detailed in the announcement. The offering's size and pricing details were also not disclosed.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:04 pm

DTIL

Precision BioSciences has announced a proposed public offering of its common stock and warrants, although the specific terms of the offering have not been disclosed. This move could potentially dilute current shareholders but also provide the company with necessary capital for its operations and development projects.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:04 pm

SIDU

Sidus Space announced its intention to sell shares of its Class A common stock in an underwritten public offering, aiming to use the net proceeds for working capital and general corporate purposes. No specific terms of the offering were disclosed.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 9:02 pm

KODK

Eastman Kodak Co. is considering a pension reversion strategy to access a $1.2 billion surplus in its pension fund. This move would involve selling illiquid investments and liquidating positions to free up funds. The company is also disbanding a team that managed the pension fund.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 8:48 pm

IART

Analysts have provided diverse opinions on Integra Lifesciences (NASDAQ:IART) with recent ratings ranging from bullish to bearish. Over the past quarter, there have been 3 somewhat bullish and 2 indifferent ratings. The average 12-month price target for IART is $48.6, reflecting a 9.21% increase from the previous target of $44.50. Key analysts from JMP Securities, Truist Securities, and Wells Fargo have adjusted their ratings and price targets, indicating a nuanced view of the company's financial health and market position. Integra Lifesciences, a medical equipment company, faces challenges in revenue growth and debt management but excels in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 8:01 pm